E-LIB Suche - Ergebnisse für: Arcaini L

1

Exposure to obinutuzumab does not affect outcomes of SARS‐C..:

Pinto, A. ; Caltagirone, M. ; Battista, M....
British Journal of Haematology. , 2024

Link: https://doi.org/10.1111/..

2

CART‐SIE REAL LIFE STUDY: PRIMARY MEDIASTINAL B‐CELL LYMPHO..:

Chiappella, A. ; Dodero, A. ; Guidetti, A....
Hematological Oncology. 41 (2023) S2 - p. 198-199 , 2023

Link: https://doi.org/10.1002/..

3

MYC ALTERATIONS IN HIV‐ASSOCIATED B CELL LYMPHOMAS: RESULTS..:

Pagani, C. ; Rusconi, C. ; Pria, A. Dalla...
Hematological Oncology. 41 (2023) S2 - p. 653-654 , 2023

Link: https://doi.org/10.1002/..

4

A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PR..:

Davies, A. J. ; Zucca, E. ; Ceriani, L....
Hematological Oncology. 41 (2023) S2 - p. 48-50 , 2023

Link: https://doi.org/10.1002/..

5

Phase 1 trial of EO2463 peptide‐based immunotherapy as mono..:

Pinto, A. A. ; Bosch, F. ; Bisneto, J. C. Villasboas...
Hematological Oncology. 41 (2023) S2 - p. 581-582 , 2023

Link: https://doi.org/10.1002/..

6

The Italian CART‐SIE real life multicenter observational st..:

Chiappella, A. ; Dodero, A. ; Ljevar, S....
Hematological Oncology. 41 (2023) S2 - p. 519-520 , 2023

Link: https://doi.org/10.1002/..

7

RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE I..:

Thieblemont, C. ; Lamy, T. ; Tani, M....
Hematological Oncology. 41 (2023) S2 - p. 104-106 , 2023

Link: https://doi.org/10.1002/..

8

P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL..:

Zinzani, P. L. ; Ansell, S. M. ; Bosch, F....
HemaSphere. 6 (2022) - p. 1005-1006 , 2022

Link: https://doi.org/10.1097/..

9

P1144: RADIOIMMUNOTHERAPY (RIT) VERSUS AUTOLOGOUS HEMATOPOI..:

Ladetto, M. ; Tavarozzi, R. ; Evangelista, A....
HemaSphere. 6 (2022) - p. 1032-1033 , 2022

Link: https://doi.org/10.1097/..

10

P1292: MOLECULAR CHARACTERIZATION OF DIFFUSE LARGE B-CELL L..:

Sciarra, R. ; Merli, M. ; Cristinelli, C....
HemaSphere. 6 (2022) - p. 1177-1178 , 2022

Link: https://doi.org/10.1097/..

11

PB2112: MINDWAY: A PHASE IB/II DOSE OPTIMIZATION STUDY TO A..:

Greil, R. ; Kopeckova, K. ; Arcaini, L....
HemaSphere. 6 (2022) - p. 1983-1984 , 2022

Link: https://doi.org/10.1097/..

12

Managing hematological cancer patients during the COVID-19 ..:

Buske, C. ; Dreyling, M. ; Alvarez-Larrán, A....
ESMO Open. 7 (2022) 2 - p. 100403 , 2022

Link: https://doi.org/10.1016/..

13

P984: MUTATIONAL PATTERNS IN PH-NEGATIVE MYELOPROLIFERATIVE..:

Casetti, I. C. ; Pietra, D. ; Ferretti, V. V....
HemaSphere. 6 (2022) - p. 874-875 , 2022

Link: https://doi.org/10.1097/..

14

GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE ..:

Bonfiglio, F. ; Bruscaggin, A. ; Guidetti, F....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

15

PROGNOSTIC FACTORS, MANAGEMENT AND OUTCOME OF AN INTERNATIO..:

Ferreri, A. J.M. ; Tarantino, V. ; Cabras, G....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..